Ten Hoorn S, Waasdorp C, van Oijen MGH, Damhofer H, et al. Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer. BMC Cancer 2022;22:394.
PMID: 35413826